SCHEMBL1268680

SCHEMBL1268680

O=C1CCc2ccccc21.O=C1CCc2ccccc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.74
MAOB P27338 3/20 0.74
CYP2A6 P11509 2/20 0.74
CES1 P23141 2/20 0.68
PBRM1 Q86U86 1/20 0.50
GRM5 P41594 1/20 0.50
PDPK1 O15530 1/20 0.50
PARP1 P09874 1/20 0.50
PARP10 Q53GL7 1/20 0.50
PARP11 Q9NR21 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
HSD17B10 Q99714 1/20 0.50
BCHE P06276 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SRD5A1 P18405 3/20 0.47
TYMS P04818 1/20 0.46
SRD5A2 P31213 1/20 0.44
HSD17B1 P14061 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29353311 1.00 MAOA (0.74) MAOAMAOBCYP2A6CES1PBRM1
SCHEMBL24746 1.00 MAOA (0.74) MAOAMAOBCYP2A6CES1PBRM1
SCHEMBL16552853 0.97 MAOA (0.71) MAOAMAOBCYP2A6CES1PBRM1
Benzene SCHEMBL28357254 0.97 MAOB (0.71) MAOAMAOBCYP2A6CES1PBRM1
Bromide SCHEMBL28903594 0.97 MAOA (0.71) MAOAMAOBCYP2A6CES1PBRM1
SCHEMBL31454252 0.97 MAOA (0.71) MAOAMAOBCYP2A6CES1PBRM1
Hydrochloric Acid SCHEMBL28796491 0.97 MAOA (0.71) MAOAMAOBCYP2A6CES1PBRM1
Biphenyl SCHEMBL3089519 0.91 MAOB (0.63) MAOAMAOBCYP2A6CES1PBRM1
SCHEMBL5105222 0.91 MAOB (0.63) MAOAMAOBCYP2A6CES1PBRM1
SCHEMBL5050048 0.91 MAOA (0.91) MAOAMAOBCYP2A6CES1PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884109-B2 immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection WYETH LLC (US) 2011-02-08 US disclosed
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2008-11-20 US disclosed
WO-2000009659-A1 METHOD FOR PRODUCING INDANE DERIVATIVES LONZA AG (CH) 2000-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION TPMT, P2RY4, P2RY1 MAOA 1365/4885MAOB 943/4885CYP2A6 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.